BME100 s2014:T Group11 L1

From OpenWetWare
Jump to: navigation, search
Owwnotebook icon.png BME 100 Fall 2013 Home
People
Lab Write-Up 1 | Lab Write-Up 2 | Lab Write-Up 3
Lab Write-Up 4 | Lab Write-Up 5 | Lab Write-Up 6
Course Logistics For Instructors
Photos
Wiki Editing Help
BME494 Asu logo.png

OUR TEAM

Name: Allan Ross
Name: Deven Govin
Name: Hillary Bratlien
Name: Sharon Li
Name: Osama Wali

LAB 1 WRITE-UP

Independent and Dependent Variables

Independent Variable: The dosage of lipopolysaccharide. It has been shown to increase Inflammotin protein levels at a 10mg dosage.

Dependent Variable: The level of Inflammotin measured in blood samples. It has been shown that the levels of this protein can be affected by lipopolysaccharide.

Experimental Design

Groups
Group 1 (10 Members)

Negative Control 0mg - The control group should provide a baseline level of Inflammotin to compare the following groups with. 10 permanent members. Will be tested at each stage of the experiment to determine natural variances in Inflammotin. They will never receive lipopolysaccharide.

Group 2 (10 Members)

0mg - This group of subjects will be tested to determine their baseline levels of Inflammotin before dosage is administered.

10mg - The first stage of testing will be giving this group a 10mg dosage to verify prior study. Expected to see an increase in protein levels.

5mg - After the test subjects have returned to their baseline protein levels (within 95% of initial levels), the dosage will be halved to 5mg.

2.5mg or 7.5mg - After the test subjects have returned to their baseline protein levels (within 95% of initial levels), they will receive their next dose. If the protein levels increased at the 5mg dosage, this group will be administered a dosage of 2.5mg. If no increase in Inflammotin is measured in the first group, the dosage will be raised to 7.5 for this group.

1.25mg, 3.75mg, 6.25mg or 8.75mg - After the test subjects have returned to their baseline protein levels (within 95% of initial levels), they will receive their next dose. If the protein levels increased in the previous stage increased, the dosage will be reduced by 1.25mg. If there was no change in the protein levels, the dosage will be raised by 1.25mg.



Number of subjects per group
10 (5 males, 5 females)





Subject Selection

20 subjects - 10 per group

65-75 years of age - shows a decent range of elderly subjects. Average age of subjects will be the same in each group.

10 males & 10 females - accounts for gender variance

Passes a basic physical - determines that all subjects have similar health to eliminate possible bias.

No conflicting medications - Biochemical report will be done to find possible conflicts or interactions with lipopolysaccharide.

A newspaper advertisement will be posted, inviting elderly candidates to volunteer for the study. When candidates respond, a survey will determine if they'll be eliminated immediately.

After a 50 viable applicants have passed the screening, the groups will be chosen randomly. (10 men and 10 women)





Sources of Error and Bias

Gender - Even numbers of men and women will be included in each group Health - Physical examination will determine that subjects have similar health Conflicting medications - Biochemical report will determine which medications could cause an error.